PMGC Holdings Inc. ELAB
- Market cap
- $3.7M
- P/E
- 0.0×
Follow ELAB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 1,815,579.00 | 10,256.84 | 300.00 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 5,003,452.50 | 4,586,105.50 | 23,991.58 |
High Price
|
|||
| — | — | — | — | — | — | 16 | 18 | 3 | 34 |
Employees
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | 1 | 2 | — | 1 |
Revenue
|
|||
| — | — | — | — | — | — | 58.37% | 66.25% | — | 31.40% |
Gross Margin
|
|||
| — | — | — | — | — | — | (2) | (2) | (4) | (8) |
EBT
|
|||
| — | — | — | — | — | — | (234.93%) | (96.74%) | 0.00% | (1,313.30%) |
EBT Margin
|
|||
| — | — | — | — | — | — | (2) | (4) | (6) | (8) |
Net Income
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | 0.08 | 0.00 | 0.00 | 295.05 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | (0.19) | (470,188.30) | (65,913.31) | (3,806.90) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | (0.17) | 0.00 | (54,870.00) | (2,966.95) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | (4,715.00) | (224.15) |
Capex/Sh
|
|||
| — | — | — | — | — | — | (0.17) | 0.00 | (59,585.00) | (3,191.10) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | 0.12 | 0.00 | 66,596.00 | 3,918.70 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 10 | 0 | 0 | 0 |
Shares
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | 27,782,590.20 | 0.00 | — | 0.41 |
PS Ratio
|
|||
| — | — | — | — | — | — | 0.00 | 0.00 | — | 0.09 |
PB Ratio
|
|||
| — | — | — | — | — | — | 27,782,589.87 | (1.94) | — | (3.01) |
EV/Sales
|
|||
| — | — | — | — | — | — | (14,963,278.66) | 0.73 | — | 0.81 |
EV/FCF
|
|||
| — | — | — | — | — | — | (2) | (5) | (5) | (6) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | 0 | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | (2) | (5) | (6) | (6) |
FCF
|
|||
| — | — | — | — | — | — | 1 | 4 | 4 | 3 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 1 | 0 |
Total Debt
|
|||
| — | — | — | — | — | — | (1) | (3) | (3) | (6) |
Net Debt
|
|||
| — | — | — | — | — | — | 1 | 4 | 7 | 8 |
Sh' Equity
|
|||
| — | — | — | — | — | — | 0.00% | (121.48%) | (88.07%) | (70.88%) |
ROA
|
|||
| — | — | — | — | — | — | 0.00% | (142.57%) | (71.34%) | (220.80%) |
ROIC
|
|||
| — | — | — | — | — | — | 0.00% | (173.52%) | (119.12%) | (106.89%) |
ROE
|
|||
PMGC Holdings Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GOVX GeoVax Labs Inc. | $3.7M | 0.0× | Compare |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | $3.6M | 0.0× | Compare |
| EOCN Galmed Pharmaceuticals Ltd. | $3.8M | 0.0× | Compare |
| JAGX Jaguar Animal Health, Inc. | $3.8M | 0.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| JUNS Jupiter Neurosciences, Inc. | $3.8M | 0.0× | Compare |
| BRTX Biorestorative Therapies, Inc. | $3.5M | 0.0× | Compare |
| REVB Revelation Biosciences, Inc. | $3.5M | 0.0× | Compare |
| IOBTQ IO Biotech, Inc. | $3.5M | 0.0× | Compare |
PMGC Holdings Inc. (ELAB) key facts
- PMGC Holdings Inc. (ELAB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- As of September 25, 2026, ELAB traded at $4.57, a market capitalization of $3.7 million.
- Return on equity was −106.9% and debt-to-equity 0.02.
PMGC Holdings Inc. (ELAB) Latest News
18 Sep
PMGC Holdings Inc. (ELAB) secured a five-year royalty stream from Elevai Skincare sale under executed payment agreement with Longevity Health Holdings. Royalty agreement creates five-year revenue stream from skincare asset sale.
1 Sep
PMGC Holdings Inc. subsidiary NorthStrive Biosciences expands its AI-driven drug discovery program via partnership with Yuva Biosciences, advancing four novel AI-discovered compounds toward lead nomination for cardiac disease and obesity therapeutic applications. Pipeline expansion through AI compounds advances early-stage development in cardiac and obesity areas, supporting potential future therapeutic positioning.
25 Aug
PMGC Holdings (ELAB) signed term sheet with Orbit2Orbit for NorthStrive Biosciences to run spaceflight study of EL-22 and EL-32 myostatin assets targeting microgravity-induced muscle loss. Early-stage space biotech partnership may lift investor sentiment and positioning without near-term revenue or operational shifts.
21 Aug
PMGC Holdings Inc. (ELAB) subsidiary NorthStrive Biosciences filed two U.S. patent applications targeting muscle loss induced by microgravity during long-duration spaceflight. Patent filings advance space biotech positioning but represent early-stage steps unlikely to immediately shift financials or core trajectory.
14 Aug
PMGC Holdings reports Q2 2026 results with total assets at $36.6 million, up 184% from year-end 2025 and 290% year-over-year. Quarterly revenue nearly doubled sequentially. Company files Form 10-Q. Asset growth and sequential revenue rise point to stronger balance sheet without indicating major strategic shifts.
28 Jul
PMGC Holdings Inc. announces strategic investment in Precision Aerospace & Defense Group and long-term aerospace and defense manufacturing agreement through A&B Aerospace Inc. Strategic investment plus long-term manufacturing agreement expands PMGC Holdings into aerospace and defense with major growth potential.
27 Jul
NorthStrive Defense Tech, linked to PMGC Holdings Inc. (ELAB), engages Deploy360 to validate its patented GPS-denied drone navigation technology under an option to license. Validation engagement for core patented drone tech under license option signals major strategic progress likely to lift ELAB trajectory and investor interest.
13 Jul
PMGC Holdings Inc. (ELAB) subsidiary NorthStrive Defense Tech signed an exclusive license agreement with Florida State University Research Foundation for multi-domain drone payload technology covering defense, aerospace and maritime applications. Exclusive multi-domain drone payload license directly expands ELAB technology access and market reach in defense sectors.
10 Jul
PMGC Holdings advances EL-22 FACS analysis to support manufacturing comparability. EL-22 FACS analysis advancement aids manufacturing comparability at PMGC Holdings.
NorthStrive Biosciences advances EL-22 manufacturing characterization via quantitative FACS analysis of latent myostatin antigen expression. EL-22 manufacturing progress supports ongoing product development in the pipeline.
6 Jul
PMGC Holdings Inc. merges AGA Precision Systems into A&B Aerospace. Merger of AGA Precision Systems into A&B Aerospace marks major strategic restructuring for PMGC Holdings.
1 Jul
NorthStrive Biosciences, part of PMGC Holdings Inc. (ELAB), reports positive Phase III results from its AI-driven drug discovery program conducted with Yuva Biosciences. Positive Phase III results advance AI drug discovery program and can materially lift valuation, pipeline value, and investor sentiment for ELAB.
18 Jun
NorthStrive Biosciences filed two new U.S. patent applications targeting muscle preservation technologies for GLP-1 drugs and next-generation obesity treatments. Patent filings add IP assets in obesity treatment space that may support future product development and market positioning.
8 Jun
NorthStrive Defense Tech, tied to PMGC Holdings Inc. (ELAB), signed a binding agreement to acquire an exclusive license for patented multi-domain drone payload technology for defense, aerospace and maritime applications. Exclusive license deal gives PMGC Holdings direct access to patented drone technology with clear defense and aerospace revenue potential.
1 Jun
PMGC Holdings Inc. (ELAB) signed a non-binding letter of intent to acquire a majority stake in a U.S.-based precision machining manufacturing company serving aerospace, space, defense, and semiconductor markets. Non-binding acquisition targets expansion into aerospace, defense, and semiconductor manufacturing sectors.
18 May
GB Capital Ltd. co-advised on the acquisition of A&B Aerospace Inc. involving PMGC Holdings Inc. (ELAB). Acquisition advisory signals potential strategic expansion for PMGC Holdings Inc. (ELAB) in aerospace.
15 May
PMGC Holdings Inc. (NASDAQ: ELAB) reports Q1 2026 results and files Form 10-Q, with total assets exceeding $26.0 million, up 102% from year-end 2025 and 193% year-over-year. Total assets doubled quarter-over-quarter and nearly tripled year-over-year, indicating major financial strengthening with potential to alter trajectory and boost investor sentiment.
PMGC Holdings Inc. reported Q1 2026 results and filed its Form 10-Q, with total assets exceeding $26.0 million, up 102% from year-end 2025 and 193% year-over-year. Quarterly results with substantial asset growth indicate moderate financial improvement without evidence of major strategic or operational shifts.
13 May
PMGC Holdings Inc. (ELAB) acquires precision parts manufacturer serving Boeing and Honeywell, expanding its capabilities in aerospace and defense supply chains. Acquisition adds high-profile clients like Boeing and Honeywell, bolstering PMGC's strategic position and growth potential in precision manufacturing.
PMGC Holdings (NASDAQ: ELAB) acquires A&B Aerospace, Inc. Acquisition of A&B Aerospace marks a major strategic expansion for PMGC Holdings in the aerospace sector.
28 Apr
NorthStrive Biosciences filed a new U.S. patent application covering EL-22 formulations and dosing for muscle-wasting conditions related to GLP-1 use, sarcopenia, muscle disuse atrophy, and certain neurological disorders. Patent filing expands EL-22's IP protection into high-demand areas like GLP-1-induced muscle wasting, enhancing ELAB's pipeline and market potential.
NorthStrive Biosciences filed a new U.S. patent application for EL-22, a compound targeting muscle preservation in humans, advancing PMGC Holdings Inc. (ELAB) innovation pipeline. Patent filing for EL-22 enhances PMGC Holdings' IP portfolio and competitive edge in muscle preservation therapeutics.
23 Apr
NorthStrive Defense Tech, part of PMGC Holdings Inc. (ELAB), acquires option for patented GPS-denied autonomous drone navigation technology designed for defense and counter-unmanned aircraft systems. Strategic acquisition of advanced drone navigation tech positions ELAB strongly in high-demand defense and counter-UAS markets.
21 Apr
Univest Securities, LLC announces a $40 million equity line facility for PMGC Holdings, Inc. (NASDAQ: ELAB), enabling the company to sell up to $40 million in common stock over time for flexible capital access. The $40 million equity line offers substantial financing flexibility to support operations and growth initiatives.
SVM Machining, Inc. signs long-term agreement to supply mission-critical aerospace and defense components to Turbo-Jet Products Co., Inc. Long-term supply deal for mission-critical components secures stable revenue and strengthens aerospace/defense market position.
17 Apr
PMGC Holdings Inc. (Nasdaq: ELAB) secured a $40 million equity purchase facility agreement, enabling acceleration of its M&A strategy focused on acquiring aerospace and defense manufacturing companies. $40 million facility accelerates M&A in high-growth aerospace and defense sector, significantly enhancing strategic expansion and market positioning.
13 Apr
NorthStrive Biosciences announces U.S. arrival of EL-32 Working Cell Bank and initiation of manufacturing optimization for dual Myostatin assets targeting muscle preservation with GLP-1 therapies, in collaboration with Modulant Biosciences. EL-32 cell bank arrival and manufacturing optimization initiation advance PMGC Holdings' pipeline for high-demand muscle preservation therapies alongside GLP-1 drugs.
9 Apr
AGA Precision Systems, part of PMGC Holdings Inc. (ELAB), signed its second long-term supply agreement to manufacture aerospace and defense components for a Tier 1 firm. Second long-term supply agreement with Tier 1 aerospace firm secures recurring revenue and strengthens PMGC Holdings' position in high-demand defense sector.
8 Apr
PMGC Holdings Inc. (NASDAQ: ELAB) fully utilized its $20 million equity financing facility, strengthening its cash position and advancing its multi-sector acquisition strategy. Full drawdown of $20M financing bolsters liquidity and fuels multi-sector acquisitions, enabling significant strategic expansion.
6 Apr
NorthStrive Defense Tech, part of PMGC Holdings Inc. (ELAB), acquires an option for multi-domain drone payload technology targeting defense and commercial applications. Acquiring drone payload technology option represents a major strategic expansion into high-growth defense and commercial drone sectors.